APOBEC3 proteins can copackage and comutate HIV-1 genomes

Nucleic Acids Research

Volumn 44, Issue 16, 2016, Pages 7848-7865

  Desimmie, Belete A ^a   Burdick, Ryan C ^a   Izumi, Taisuke ^a   Doi, Hibiki ^a   Shao, Wei ^a   Alvord, W Gregory ^b   Sato, Kei ^c,d   Koyanagi, Yoshio ^c   Jones, Sara ^e   Wilson, Eleanor ^a,f   Hill, Shawn ^a   Maldarelli, Frank ^a   Hu, Wei Shau ^a   Pathak, Vinay K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Data Management Services Inc   (United States)

^c KYOTO UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3D; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; COMPLEMENTARY DNA; CYTIDINE DEAMINASE; GUANINE; TRINUCLEOTIDE; UNCLASSIFIED DRUG; VIRUS DNA; APOBEC3 PROTEIN, HUMAN; CYTOSINE DEAMINASE; NUCLEOTIDE; VIF PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; CELL LINE; DNA SEQUENCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MUTATION; MUTATION RATE; PHYSIOLOGY; PROVIRUS; VIROLOGY;

ADULT; CELL LINE; CYTOSINE DEAMINASE; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; MUTATION RATE; NUCLEOTIDES; PROVIRUSES; SEQUENCE ANALYSIS, DNA; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRION;

EID: 84988002393     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkw653     Document Type: Article

References (95)

1. Zheng, Y.H., Jeang, K.T. and Tokunaga, K. (2012) Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology, 9, 112.
2. Malim, M.H. and Bieniasz, P.D. (2012) HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med., 2, a006940.
3. Desimmie, B.A., Delviks-Frankenberrry, K.A., Burdick, R.C., Qi, D., Izumi, T. and Pathak, V.K. (2014) Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J. Mol. Biol., 426, 1220-1245.
4. Simon, V., Bloch, N. and Landau, N.R. (2015) Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat. Immunol., 16, 546-553.
5. Sheehy, A.M., Gaddis, N.C., Choi, J.D. and Malim, M.H. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 418, 646-650.
6. OhAinle, M., Kerns, J.A., Malik, H.S. and Emerman, M. (2006) Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol., 80, 3853-3862.
7. Hultquist, J.F., Lengyel, J.A., Refsland, E.W., LaRue, R.S., Lackey, L., Brown, W.L. and Harris, R.S. (2011) Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol., 85, 11220-11234.
8. Harari, A., Ooms, M., Mulder, L.C. and Simon, V. (2009) Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol., 83, 295-303.
9. Wiegand, H.L., Doehle, B.P., Bogerd, H.P. and Cullen, B.R. (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J., 23, 2451-2458.
10. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L. and Trono, D. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature, 424, 99-103.
11. Sheehy, A.M., Gaddis, N.C. and Malim, M.H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med., 9, 1404-1407.
12. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P. and Yu, X.F. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science, 302, 1056-1060.
13. Marin, M., Golem, S., Rose, K.M., Kozak, S.L. and Kabat, D. (2008) Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J. Virol., 82, 987-998.
14. Dang, Y., Wang, X., Esselman, W.J. and Zheng, Y.H. (2006) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol., 80, 10522-10533.
15. Yu, Q., Chen, D., Konig, R., Mariani, R., Unutmaz, D. and Landau, N.R. (2004) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem., 279, 53379-53386.
16. Refsland, E.W., Hultquist, J.F. and Harris, R.S. (2012) Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog., 8, e1002800.
17. Ulenga, N.K., Sarr, A.D., Thakore-Meloni, S., Sankale, J.L., Eisen, G. and Kanki, P.J. (2008) Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. J. Infect. Dis., 198, 486-492.
18. Koning, F.A., Newman, E.N., Kim, E.Y., Kunstman, K.J., Wolinsky, S.M. and Malim, M.H. (2009) Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol., 83, 9474-9485.
19. Ying, S., Zhang, X., Sarkis, P.T., Xu, R. and Yu, X. (2007) Cell-specific regulation of APOBEC3F by interferons. Acta Biochim. Biophys. Sin., 39, 297-304.
20. Pillai, S.K., Abdel-Mohsen, M., Guatelli, J., Skasko, M., Monto, A., Fujimoto, K., Yukl, S., Greene, W.C., Kovari, H., Rauch, A., et al. (2012) Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proc. Natl. Acad. Sci. U.S.A., 109, 3035-3040.
21. Chen, K., Huang, J., Zhang, C., Huang, S., Nunnari, G., Wang, F.X., Tong, X., Gao, L., Nikisher, K. and Zhang, H. (2006) Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J. Virol., 80, 7645-7657.
22. Ebrahimi, D., Anwar, F. and Davenport, M.P. (2012) APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome. Retrovirology, 9, 113.
23. Lassen, K.G., Wissing, S., Lobritz, M.A., Santiago, M. and Greene, W.C. (2010) Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif. J. Biol. Chem., 285, 29326-29335.
24. Yang, Y., Guo, F., Cen, S. and Kleiman, L. (2007) Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology, 365, 92-100.
25. Wang, T., Tian, C., Zhang, W., Sarkis, P.T. and Yu, X.F. (2008) Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J. Mol. Biol., 375, 1098-1112.
26. Zhang, W., Du, J., Yu, K., Wang, T., Yong, X. and Yu, X.F. (2010) Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions. J. Virol., 84, 12903-12913.
27. Bach, D., Peddi, S., Mangeat, B., Lakkaraju, A., Strub, K. and Trono, D. (2008) Characterization of APOBEC3G binding to 7SL RNA. Retrovirology, 5, 54.
28. Svarovskaia, E.S., Xu, H., Mbisa, J.L., Barr, R., Gorelick, R.J., Ono, A., Freed, E.O., Hu, W.S. and Pathak, V.K. (2004) Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem., 279, 35822-35828.
29. Zennou, V., Perez-Caballero, D., Gottlinger, H. and Bieniasz, P.D. (2004) APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol., 78, 12058-12061.
30. Luo, K., Liu, B., Xiao, Z., Yu, Y., Yu, X., Gorelick, R. and Yu, X.F. (2004) Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol., 78, 11841-11852.
31. Khan, M.A., Kao, S., Miyagi, E., Takeuchi, H., Goila-Gaur, R., Opi, S., Gipson, C.L., Parslow, T.G., Ly, H. and Strebel, K. (2005) Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol., 79, 5870-5874.
32. Wang, T., Tian, C., Zhang, W., Luo, K., Sarkis, P.T., Yu, L., Liu, B., Yu, Y. and Yu, X.F. (2007) 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol., 81, 13112-13124.
33. Alce, T.M. and Popik, W. (2004) APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem., 279, 34083-34086.
34. Schafer, A., Bogerd, H.P. and Cullen, B.R. (2004) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology, 328, 163-168.
35. Khan, M.A., Goila-Gaur, R., Kao, S., Miyagi, E., Walker, R.C. Jr. and Strebel, K. (2009) Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization. Retrovirology, 6, 99.
36. Apolonia, L., Schulz, R., Curk, T., Rocha, P., Swanson, C.M., Schaller, T., Ule, J. and Malim, M.H. (2015) Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1. PLoS Pathog., 11, e1004609.
37. Izumi, T., Burdick, R., Shigemi, M., Plisov, S., Hu, W.S. and Pathak, V.K. (2013) Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity. J. Virol., 87, 11047-11062.
38. Navarro, F., Bollman, B., Chen, H., Konig, R., Yu, Q., Chiles, K. and Landau, N.R. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology, 333, 374-386.
39. Iwatani, Y., Takeuchi, H., Strebel, K. and Levin, J.G. (2006) Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol., 80, 5992-6002.
40. Chiu, Y.L., Soros, V.B., Kreisberg, J.F., Stopak, K., Yonemoto, W. and Greene, W.C. (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature, 435, 108-114.
41. Chiu, Y.L., Witkowska, H.E., Hall, S.C., Santiago, M., Soros, V.B., Esnault, C., Heidmann, T. and Greene, W.C. (2006) High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A., 103, 15588-15593.
42. Chaipan, C., Smith, J.L., Hu, W.S. and Pathak, V.K. (2013) APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J. Virol., 87, 444-453.
43. Refsland, E.W., Stenglein, M.D., Shindo, K., Albin, J.S., Brown, W.L. and Harris, R.S. (2010) Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res., 38, 4274-4284.
44. Armitage, A.E., Deforche, K., Chang, C.H., Wee, E., Kramer, B., Welch, J.J., Gerstoft, J., Fugger, L., McMichael, A., Rambaut, A., et al. (2012) APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete all or nothing phenomenon. PLoS Genet., 8, e1002550.
45. Armitage, A.E., Deforche, K., Welch, J.J., Van Laethem, K., Camacho, R., Rambaut, A. and Iversen, A.K. (2014) Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections. J. Virol., 88, 12882-12894.
46. Gillick, K., Pollpeter, D., Phalora, P., Kim, E.Y., Wolinsky, S.M. and Malim, M.H. (2013) Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J. Virol., 87, 1508-1517.
47. Kieffer, T.L., Kwon, P., Nettles, R.E., Han, Y., Ray, S.C. and Siliciano, R.F. (2005) G->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J. Virol., 79, 1975-1980.
48. Kim, E.Y., Lorenzo-Redondo, R., Little, S.J., Chung, Y.S., Phalora, P.K., Maljkovic Berry, I., Archer, J., Penugonda, S., Fischer, W., Richman, D.D., et al. (2014) Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. PLoS Pathog., 10, e1004281.
49. Sato, K., Takeuchi, J.S., Misawa, N., Izumi, T., Kobayashi, T., Kimura, Y., Iwami, S., Takaori-Kondo, A., Hu, W.S., Aihara, K., et al. (2014) APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLoS Pathog., 10, e1004453.
50. Land, A.M., Ball, T.B., Luo, M., Pilon, R., Sandstrom, P., Embree, J.E., Wachihi, C., Kimani, J. and Plummer, F.A. (2008) Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J. Virol., 82, 8172-8182.
51. Wichroski, M.J., Robb, G.B. and Rana, T.M. (2006) Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog., 2, e41.
52. Ara, A., Love, R.P. and Chelico, L. (2014) Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms. PLoS Pathog., 10, e1004024.
53. Feng, Y., Love, R.P., Ara, A., Baig, T.T., Adolph, M.B. and Chelico, L. (2015) Natural polymorphisms and oligomerization of human APOBEC3H contribute to single-stranded DNA scanning ability. J. Biol. Chem., 290, 27188-27203.
54. Unutmaz, D., KewalRamani, V.N., Marmon, S. and Littman, D.R. (1999) Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med., 189, 1735-1746.
55. Yee, J.K., Friedmann, T. and Burns, J.C. (1994) Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol., 43 Pt A, 99-112.
56. Boussif, O., Lezoualch, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B. and Behr, J.P. (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U.S.A., 92, 7297-7301.
57. Chen, J., Nikolaitchik, O., Singh, J., Wright, A., Bencsics, C.E., Coffin, J.M., Ni, N., Lockett, S., Pathak, V.K. and Hu, W.S. (2009) High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proc. Natl. Acad. Sci. U.S.A., 106, 13535-13540.
58. Burdick, R.C., Hu, W.S. and Pathak, V.K. (2013) Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes. Proc. Natl. Acad. Sci. U.S.A., 110, E4780-E4789.
59. Zenklusen, D., Larson, D.R. and Singer, R.H. (2008) Single-RNA counting reveals alternative modes of gene expression in yeast. Nat. Struct. Mol. Biol., 15, 1263-1271.
60. OhAinle, M., Kerns, J.A., Li, M.M., Malik, H.S. and Emerman, M. (2008) Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe, 4, 249-259.
61. Kearney, M.F., Spindler, J., Shao, W., Yu, S., Anderson, E.M., O'Shea, A., Rehm, C., Poethke, C., Kovacs, N., Mellors, J.W., et al. (2014) Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog., 10, e1004010.
62. Palmer, S., Kearney, M., Maldarelli, F., Halvas, E.K., Bixby, C.J., Bazmi, H., Rock, D., Falloon, J., Davey, R.T. Jr, Dewar, R.L., et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol., 43, 406-413.
63. Agresti, A. (1990) Categorical Data Analysis. 2nd edn. Wiley, NY.
64. Team, C. (2012) R: a Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna.
65. Burdick, R., Smith, J.L., Chaipan, C., Friew, Y., Chen, J., Venkatachari, N.J., Delviks-Frankenberry, K.A., Hu, W.S. and Pathak, V.K. (2010) P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages. J. Virol., 84, 10241-10253.
66. Wang, X., Li, X., Ma, J., Zhang, L., Ma, L., Mi, Z., Zhou, J., Guo, F., Kleiman, L. and Cen, S. (2014) Human APOBEC3F incorporation into human immunodeficiency virus type 1 particles. Virus Res., 191, 30-38.
67. Bishop, K.N., Holmes, R.K., Sheehy, A.M., Davidson, N.O., Cho, S.J. and Malim, M.H. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol., 14, 1392-1396.
68. Ooms, M., Brayton, B., Letko, M., Maio, S.M., Pilcher, C.D., Hecht, F.M., Barbour, J.D. and Simon, V. (2013) HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host Microbe, 14, 411-421.
69. Liddament, M.T., Brown, W.L., Schumacher, A.J. and Harris, R.S. (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol., 14, 1385-1391.
70. Mbisa, J.L., Barr, R., Thomas, J.A., Vandegraaff, N., Dorweiler, I.J., Svarovskaia, E.S., Brown, W.L., Mansky, L.M., Gorelick, R.J., Harris, R.S., et al. (2007) Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol., 81, 7099-7110.
71. Li, X.Y., Guo, F., Zhang, L., Kleiman, L. and Cen, S. (2007) APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem, 282, 32065-32074.
72. Iwatani, Y., Chan, D.S., Wang, F., Maynard, K.S., Sugiura, W., Gronenborn, A.M., Rouzina, I., Williams, M.C., Musier-Forsyth, K. and Levin, J.G. (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res., 35, 7096-7108.
73. Holmes, R.K., Koning, F.A., Bishop, K.N. and Malim, M.H. (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem., 282, 2587-2595.
74. Yu, Q., Konig, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., Coffin, J.M. and Landau, N.R. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol., 11, 435-442.
75. Senavirathne, G., Jaszczur, M., Auerbach, P.A., Upton, T.G., Chelico, L., Goodman, M.F. and Rueda, D. (2012) Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution. J. Biol. Chem., 287, 15826-15835.
76. Losey, H.C., Ruthenburg, A.J. and Verdine, G.L. (2006) Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA. Nat. Struct. Mol. Biol., 13, 153-159.
77. Janini, M., Rogers, M., Birx, D.R. and McCutchan, F.E. (2001) Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J. Virol., 75, 7973-7986.
78. Li, Y., Kappes, J.C., Conway, J.A., Price, R.W., Shaw, G.M. and Hahn, B.H. (1991) Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J. Virol., 65, 3973-3985.
79. Vartanian, J.P., Henry, M. and Wain-Hobson, S. (2002) Sustained G->A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. J. Gen. Virol., 83, 801-805.
80. Russell, R.A., Moore, M.D., Hu, W.S. and Pathak, V.K. (2009) APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology, 6, 16.
81. Refsland, E.W., Hultquist, J.F., Luengas, E.M., Ikeda, T., Shaban, N.M., Law, E.K., Brown, W.L., Reilly, C., Emerman, M. and Harris, R.S. (2014) Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet., 10, e1004761.
82. Bishop, K.N., Verma, M., Kim, E.Y., Wolinsky, S.M. and Malim, M.H. (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog., 4, e1000231.
83. Mitra, M., Singer, D., Mano, Y., Hritz, J., Nam, G., Gorelick, R.J., Byeon, I.J., Gronenborn, A.M., Iwatani, Y. and Levin, J.G. (2015) Sequence and structural determinants of human APOBEC3H deaminase and anti-HIV-1 activities. Retrovirology, 12, 3.
84. Delviks-Frankenberry, K.A., Nikolaitchik, O.A., Burdick, R.C., Gorelick, R.J., Keele, B.F., Hu, W.S. and Pathak, V.K. (2016) Minimal contribution of APOBEC3-Induced G-to-A hypermutation to HIV-1 recombination and genetic variation. PLoS Pathog., 12, e1005646.
85. Hersperger, A.R., Migueles, S.A., Betts, M.R. and Connors, M. (2011) Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr. Opin. HIV AIDS, 6, 169-173.
86. Goulder, P.J. and Watkins, D.I. (2008) Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol., 8, 619-630.
87. Casartelli, N., Guivel-Benhassine, F., Bouziat, R., Brandler, S., Schwartz, O. and Moris, A. (2010) The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J. Exp. Med., 207, 39-49.
88. Norman, J.M., Mashiba, M., McNamara, L.A., Onafuwa-Nuga, A., Chiari-Fort, E., Shen, W. and Collins, K.L. (2011) The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat. Immunol., 12, 975-983.
89. Monajemi, M., Woodworth, C.F., Benkaroun, J., Grant, M. and Larijani, M. (2012) Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment. Retrovirology, 9, 35.
90. Josefsson, L., King, M.S., Makitalo, B., Brannstrom, J., Shao, W., Maldarelli, F., Kearney, M.F., Hu, W.S., Chen, J., Gaines, H., et al. (2011) Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc. Natl. Acad. Sci. U.S.A., 108, 11199-11204.
91. Cha, L., Berry, C.M., Nolan, D., Castley, A., Fernandez, S. and French, M.A. (2014) Interferon-alpha, immune activation and immune dysfunction in treated HIV infection. Clin. Transl. Immunology, 3, e10.
92. Hardy, G.A., Sieg, S., Rodriguez, B., Anthony, D., Asaad, R., Jiang, W., Mudd, J., Schacker, T., Funderburg, N.T., Pilch-Cooper, H.A., et al. (2013) Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PloS One, 8, e56527.
93. Raposo, R.A., Abdel-Mohsen, M., Bilska, M., Montefiori, D.C., Nixon, D.F. and Pillai, S.K. (2013) Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells. J. Virol., 87, 11924-11929.
94. Mohanram, V., Skold, A.E., Bachle, S.M., Pathak, S.K. and Spetz, A.L. (2013) IFN-alpha induces APOBEC3G, F, and A in immature dendritic cells and limits HIV-1 spread to CD4+ T cells. J. Immunol., 190, 3346-3353.
95. Stavrou, S. and Ross, S.R. (2015) APOBEC3 proteins in viral immunity. J. Immunol., 195, 4565-4570.